Kotak said the near-term outlook for Gland Pharma is sluggish but the product pipeline and entry into new markets provide medium-term growth visibility.
Shares of Gland Pharma fell over 3 per cent today after investor Nicomac Machinery reduced its stake in the pharma firm. The large cap stock touched an intraday low of Rs 3,319.85, down 3.58 per cent on BSE. Gland Pharma stock has lost 26.13 per cent in a year and fallen 13.21 per cent in 2022.